Acne 

Actinic Keratosis 

Aesthetics

Alopecia

Biologic Treatments for Moderate to Severe Atopic Dermatitis 

Atopic Dermatitis 

COVID-19

Drug Watch

Eczema

General Dermatology 

Hidradenitis Suppurativa

Melasma

NP and PA

Pediatric Dermatology

Pigmentary Disorders 

Practice Management 

Precision Medicine and Biologics

Emerging Therapies Plaque Psoriasis

Treatments for Plaque Psoriasis 

Psoriasis 

Psoriatic Arthritis 

Rare Disease

Rosacea 

Skin Cancer (Nonmelanoma)

Skin Cancer

Vitiligo

Wound Care

News

Media

Around the Practice

Between The Lines

Case-Based Peer Perspective

DermView

Expert Perspectives

Fellows Face Off

Frontline Forum

Medical World News

Patient Perspectives

Podcasts

Readout360

Recognize and Refer

Conferences

Conference Coverage

Conference Listing

Events

Case-Based Roundtable

Publication

Dermatology Times

CME/CE

Resources

DermIQ

Interactive Tools

Job Board

Partner Perspectives

Polls

Editorial Advisory Board

Partners

Subscribe

and joined the MJH Life Sciences team in February 2023. She attended Kent State University and earned a Bachelor of Science degree in journalism with minors in public relations and creative writing. She enjoys making and listening to music, reading, and spending time with her cats, Astrid and Marceline.

Articles

Following treatment, 17.5% and 13% of patients reported residual depressive and anxiety symptoms.

2 Years of Treatment With Dupilumab Led to Improvements In Symptoms of AD and Comorbid Anxiety, Depression

, co-founder and Chief Medical Officer of Bare Dermatology, Dallas, Texas.

Dermatology Times' Spring Editor in Chief, Aaron Farberg, MD, discusses the business strategy known as buy and bill.

Understanding Buy and Bill for Medical Dermatology: A Win-Win

A 5-expert panel delves into atopic dermatitis guidelines and recommendations and recent studies to make note of.

Enhancing Atopic Dermatitis Treatment: Insights From Cutting-Edge Studies and Clinical Perspectives Part 1

ASLAN Pharmaceuticals presented new data this morning, including a 90% EASI score reduction.

New Eblasakimab Data Shows Promise for Patients With AD and Inadequate Response to Dupilumab

Ranella Hirsch, MD, FAAD

Articles